Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada

Using Canadian real-world evidence, these data demonstrate differing clinical trajectories between patients with HAE nC1-INH and AE-UNK, including diagnostic delays, varied attack characteristics, treatment responses and healthcare utilization. Despite treatment response, many patients still experienced frequent angioedema attacks. These results suggest an unmet need for treatment guidelines and therapies specifically for patients with HAE nC1-INH and AE-UNK and better understanding of the pathophysiology accounting for the reported differences between the two.

Authors

Institutions

Publication Details

Journal
Allergy Asthma and Clinical Immunology
Published
2024-09-27
DOI
https://doi.org/10.1186/s13223-024-00910-x
Citations
7
Primary Topic
Coagulation, Bradykinin, Polyphosphates, and Angioedema
Type
article
Field-Weighted Citation Impact
3.07

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada

Amin Kanani, Dawn M. Goodyear, Stephen Betschel, Chrystyna Kalicinsky et al.
7 citations
Allergy Asthma and Clinical Immunology
Coagulation, Bradykinin, Polyphosphates, and Angioedema
3.07
article

Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada

Amin Kanani, Dawn M. Goodyear, Stephen Betschel, Chrystyna Kalicinsky, Jessica Weiss, Adil Adatia, Ahmed El-Zoeiby, Susan Waserman, Jean-Nicolas Boursiquot, Michelle M L Nguyen, A. Wadhwa
article en
7 citations

Abstract

Using Canadian real-world evidence, these data demonstrate differing clinical trajectories between patients with HAE nC1-INH and AE-UNK, including diagnostic delays, varied attack characteristics, treatment responses and healthcare utilization. Despite treatment response, many patients still experienced frequent angioedema attacks. These results suggest an unmet need for treatment guidelines and therapies specifically for patients with HAE nC1-INH and AE-UNK and better understanding of the pathophysiology accounting for the reported differences between the two.

Allergy Asthma and Clinical ImmunologyVol. 20(1)
Alberta Health Services (CA), St. Michael's Hospital (CA), University of British Columbia (CA), Pediatric Oncology Group (CA), University of Alberta (CA), University of Calgary (CA), Health Sciences Centre (CA), St. Paul's Hospital (CA), Takeda (Canada) (CA), Université Laval (CA), University of Manitoba (CA), Hamilton Health Sciences (CA), McMaster University (CA)
Takeda Canada
Good health and well-being
Openalex Percentile: Top 8%
Coagulation, Bradykinin, Polyphosphates, and Angioedema
3.07
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Real-world outcomes of patients with hereditary angioedema with normal C1-inhibitor function and patients with idiopathic angioedema of unknown etiology in Canada — Amin Kanani, Dawn M. Goodyear, et al. · Allergy Asthma and Clinical Immunology (2024) | TGRS Research Map | TGRS